

Level 14, Cigna House,  
40 Mercer Street, PO Box 10-254  
Wellington 6001, New Zealand  
Phone 64 4 460 4990  
Fax 64 4 460 4995  
www.pharmac.govt.nz

23 December 2003

**To: All Pharmaceutical Suppliers, Medical Groups and Interested Parties**

**Consultation on a restriction, to one per day, on the number of Plendil ER 2.5 mg tablets that can be subsidised on a prescription**

In February 2004 the PHARMAC Board (or Chief Executive under delegated authority pursuant to section 61 of the New Zealand Public Health and Disability Act 2000) will consider a proposal to restrict the number of tablets of the Plendil ER 2.5 mg brand of felodipine subsidised on a prescription to one per day. If accepted by the PHARMAC Board (or Chief Executive) the proposal would be implemented no sooner than 1 March 2004.

Under the proposal prescriptions for Plendil ER 2.5 mg tablets for more than one tablet per day would not receive a Government subsidy. PHARMAC staff note that the 5 mg and 10 mg presentations of the Felo ER brand of felodipine are available for patients who require a dose of felodipine greater than 2.5 mg per day.

If you wish to make comments on this proposal for the Board (or Chief Executive) to consider, please forward them to Hew Norris at PHARMAC by **12 pm on Thursday, 4 February 2004**. If you have any questions regarding the proposal or the consultation process, I can be contacted on (04) 9167 515.

Yours sincerely



Hew Norris  
Therapeutic Group Manager